All In Biotech

Drug Trial Radar · NCT06735820

Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST

Early Phase Study to Evaluate the MEK Inhibitor Selumetinib With the MDM2 Inhibitor APG-115 in Patients With Neurofibromatosis Type 1 and Pre-malignant and Malignant Peripheral Nerve Sheath Tumors

Last checked: Nov 19, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Jun 1, 2026

Primary completion

Oct 1, 2027

Study completion Oct 1, 2028

Sponsor

Lead sponsor
AeRang KimAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Children's National Research Institute
First posted
Dec 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 0/1/2, multi-site study to evaluate the MEK inhibitor Selumetinib with the MDM2 Inhibitor APG-115 in patients with Neurofibromatosis Type 1 and pre-malignant and malignant peripheral nerve sheath tumors

Conditions

  • Malignant Peripheral Nerve Sheath Tumor (MPNST)
  • Neurofibromatosis 1 (NF1)
  • Atypical Neurofibroma

Interventions

  • APG-115Drug

    Combination therapy of APG-115 and Selumetinib

  • SelumetinibDrug

    Combination therapy of APG-115 and Selumetinib

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number of treated patients with adverse events as determined by the common criteria for adverse version 5 (CTCAEv5).Time frame: 15 months
  2. Tumor response by imaging using RECISTv1.1Time frame: 28 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Children's National Hospital

    Washington D.C., District of Columbia · Recruiting

  • UT Southwestern Medical Center

    Dallas, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.